Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record.

C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT I

Reinisch, W., Wang, Y., Oddens, B. J., Link, R. · 2012 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Secondary loss of response to anti‐TNF‐α therapy is observed in C rohn's disease patients. Aim: Serum C‐reactive protein (CRP) levels at baseline and after infliximab induction therapy at week 14 were assessed as predictors for maintained response or remission through 54 weeks of treatment in patients with Crohn's disease who responded to induction therapy. Methods: ACCENT I was a multicenter, randomised, placebo‐controlled study. Patients who received infliximab induction (weeks 0, 2 and 6) and maintenance (5 or 10 mg/kg every 8 weeks beginning at week 14) therapy were considered. Patients in clinical response or remission to induction therapy at week 14 (n = 212 or n = 138 respectively) were analysed. Associations between CRP levels (cut‐off points 0.5–3.0 mg/dL), baseline disease variables and maintained clinical response or remission during maintenance therapy were assessed. Results: A significant association was observed between baseline CRP levels and maintained remission. Forty‐five percent of patients with baseline CRP ≥ 0.7 mg/dL vs. 22.0% with CRP < 0.7 mg/dL maintained remission (P = 0.012). CRP normalisation during infliximab treatment (decrease from 0.5 mg/dL at baseline to < 0.5 mg/dL at week 14) resulted in higher probability of maintained response (P < 0.001) or remission (P = 0.052). At week 14 low CRP levels were associated with maintained response (56.6% of patients with CRP < 0.5 mg/dL vs. 37.2% with higher CRP, P = 0.005). No optimal predictive CRP cut‐off point was observed. Conclusions: High baseline CRP levels increased the likelihood of maintained remission. Normalised CRP levels at week 14 increased the likelihood of maintained response or remission during 1 year of infliximab maintenance therapy (Clinical trial: NCT00207662).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2011.04987.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 179

Metadata

Authors
Reinisch, W., Wang, Y., Oddens, B. J., & Link, R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-01-18
Volume
35
Issue
5
Pages
568-576
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2069485958
Cited by
179
References
0
FWCI
10.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT I. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04987.x
The paper
Reinisch, W., Wang, Y., Oddens, B. J., & Link, R. (2012). C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT I. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04987.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.